Advertisement

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

Gilles Salles, Franck Morschhauser, Thierry Lamy, Noel Milpied, Catherine Thieblemont, Hervé Tilly, Gabi Bieska, Elina Asikanius, David Carlile, Joe Birkett, Pavel Pisa and Guillaume Cartron

Article Information

Citation 
vol. 119 no. 22 5126-5132
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted January 18, 2012
  • Accepted March 11, 2012
  • Published online May 31, 2012.

Article Versions


Contributors 
  • Gilles Salles, 1Hospices Civils de Lyon, Hematologie, Université de Lyon, Unité Mixte de Recherche (UMR) 5239, Centre National de la Recherche Scientifique (CNRS), Pierre-Bénite, France;
  • Franck Morschhauser, 2Hématologie, Centre Hospitalier Universitaire (CHU), Université de Lille, Equipe d'Accueil 4481, Lille, France;
  • Thierry Lamy, 3Service d'Hématologie Clinique, CHU, Université de Rennes, UMR 917, Rennes, France;
  • Noel Milpied, 4CHU de Bordeaux 2, Bordeaux, France;
  • Catherine Thieblemont, 5Assistance Publique des Hôpitaux de Paris Hôpital Saint-Louis, Hémato-Oncologie-Université Paris Diderot, Sorbonne Paris Cité, UMR 728, Paris, France;
  • Hervé Tilly, 6Hématologie, UMR 918, Centre Henri Becquerel, Université de Rouen, Rouen, France;
  • Gabi Bieska, 7F. Hoffmann–La Roche, Basel, Switzerland;
  • Elina Asikanius, 7F. Hoffmann–La Roche, Basel, Switzerland;
  • David Carlile, 8Roche Products, Welwyn Garden City, United Kingdom; and
  • Joe Birkett, 8Roche Products, Welwyn Garden City, United Kingdom; and
  • Pavel Pisa, 7F. Hoffmann–La Roche, Basel, Switzerland;
  • Guillaume Cartron, 9Département d'Hématologie, CHU, UMR 5235, CNRS, Montpellier, France

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output